The rise of copyright’s blockbuster initially drove a surge for the drug industry, but recent developments present a uncertain outlook for investors. Generic alternatives are eating into revenue, and ongoing legal battles add further risk to the landscape. While certain companies might still see gains from related products, the general trajector… Read More